News

ivWatch Named to Inc.’s 2024 Best in Business List in Health Products Category

ivWatch, LLC, the IV safety company, is proud to announce it has been named to the Inc. 2024 Best in Business list in the Health Products category. Inc.’s annual Best in Business Awards celebrate the exceptional achievements and contributions of companies that have made a profound impact on their industries and on society at large.

Inc.’s Best in Business list recognizes companies that, through exceptional execution, have achieved significant milestones and core business wins, like customer expansion, key product launches, increased market share, and industry-defining accomplishments. Companies from a wide range of industries – such as technology, healthcare, finance, and retail – have been recognized for their success and positive influence on the business world. The full list can be found on Inc.com and in the upcoming winter print edition of Inc. magazine.

ivWatch has over 20 years of research and development under its belt since its founding, in its single-minded pursuit of improving IV safety globally, securing 69 patents for its technology in the process. Among the milestones the company has reached:

  • Over 300,000 patients monitored to date.
  • 9 million hours of patient monitoring to date.
  • Comparing January – September 2023 vs. 2024, single-use sensors sold increased 83%.
  • The company has expanded its footprint beyond the U.S. and the technology is now available in the U.K., Ireland, the Netherlands, Belgium, United Arab Emirates, Saudi Arabia, Australia, New Zealand, Canada, Qatar, Israel, and Kuwait.
  • >430% growth in product evaluations comparing 2023 completed evaluations to the evaluations completed in 2024, as of July. The evaluations completed in 2023 were located in only two countries (US and UK); as of January – July 2024, completed evaluations took place in 13 countries. An estimated total for evaluations to be completed by the end of 2024 would exceed the previous year 10 times.
  • Reached Top Ten in 2024 Startup World Cup Grand Finale.

“Being named to Inc.’s Best in Business list is a tremendous honor, and I want to thank everyone at ivWatch for their unwavering dedication toward growing our company and inventing an entirely new category with a solution we believe in that everyone around the world will one day need and benefit from,”  said ivWatch CEO Gary Warren. “We’re on a mission to solve one of the biggest problems in healthcare by reducing IV injuries, and this recognition belongs to the passionate ivWatch team who have started a movement along with our customers to keep patients safe from IV harm.”

Inc.’s Best in Business Awards are open to companies of all sizes and types, in all industries and locations. Public, private, nonprofit, subsidiary, U.S.-based, and international companies are all encouraged to apply. Inc. editors and reporters hand-review every application and select Best in Business honorees that, in each of the award categories, have had an outstanding influence on their communities, their industries, the environment, or society as a whole.

“For over 40 years, Inc. has been committed to recognizing America’s most dynamic businesses and honoring the great work they do. These businesses have had a profound impact on their industries, solving important problems, and shaping the future of business in ways that will have lasting effects,” says Inc. editor-in-chief Mike Hofman.

For more information or to see the complete list, please visit inc.com/best-in-business.

 

Read more here.

Recent News

07/17/2025

RIVANNA’s next-generation ultrasound guidance platform and AI-driven imaging software receive FDA 510(K) clearance

RIVANNA®, developers of world-first imaging-based medical technologies, announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) regarding the Accuro® 3S diagnostic ultrasound system and SpineNav-AI™ image processing software. This clearance authorizes the use of both technologies in United States hospital and clinical settings, providing anatomical guidance during needle or

07/15/2025

CEL-SCI Announces Closing of $5.7 Million Offering Priced At-The-Market Under NYSE American Rules

CEL-SCI Corporation (“CEL-SCI” or the “Company”) (NYSE American: CVM), a clinical stage cancer immunotherapy company, announced the closing of its best-efforts offering of 1,500,000 shares of its common stock. Each share of common stock was sold at an offering price of $3.82 per share, priced at-the-market under NYSE American rules. Total gross proceeds from the

07/15/2025

Civica Appoints Dave Sehgal as Chief Manufacturing Officer and Supply Chain Officer

Civica announced the appointment of Dave Sehgal, Ph.D. as its new Chief Manufacturing Officer and Supply Chain Officer, effective July 21. In this role, Dr. Sehgal will lead Civica’s manufacturing strategy and operations, reporting directly to Ned McCoy, President and CEO. “We are excited to welcome Dave to our leadership team,” said McCoy. “His deep